Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

doi:10.1007/s00535-013-0924-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

Journal of gastroenterology - 1 Dec 2014

Fujino Hatsue, Imamura Michio, Nagaoki Yuko, Kawakami Yoshiiku, Abe Hiromi, Hayes C Nelson, Kan Hiromi, Fukuhara Takayuki, Kobayashi Tomoki, Masaki Keiichi, Ono Atsushi, Nakahara Takashi, Honda Youji, Naeshiro Noriaki, Urabe Ayako, Yokoyama Satoe, Miyaki Daisuke, Murakami Eisuke, Kawaoka Tomokazu, Hiraga Nobuhiko, Tsuge Masataka, Hiramatsu Akira, Hyogo Hideyuki, Aikata Hiroshi, Takahashi Shoichi, Miki Daiki, Ochi Hidenori, Ohishi Waka, Chayama Kazuaki

Abstract excerpt

BACKGROUND: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN) treatment compared to younger patients. The efficacy of telaprevir (TVR) and PEG-IFN plus ribavirin combination therapy and the predictive value of recently identified IFN lambda (IFNL) 4 polymorphisms on the outcome of therapy for older patients have not been addressed. METHODS: We assessed predictive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Interleukins

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Regression Analysis

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 24362944
DOI: 10.1007/s00535-013-0924-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.PMID 24362944Read ↗

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.Semantic proximity Read ↗

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients.Semantic proximity Read ↗

Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C.Semantic proximity Read ↗

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C.Semantic proximity Read ↗

The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection.Semantic proximity Read ↗

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.Semantic proximity Read ↗

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories.Semantic proximity Read ↗

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.Semantic proximity Read ↗

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.Semantic proximity Read ↗

Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.